Zhejiang Huakang Pharmaceutical Co., Ltd. (SHA:605077)

SHA:605077 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	3,648	2,795	2,731	2,180	1,588	1,313
Other Revenue	13.79	13.79	51.27	19.52	6.47	6.66
Revenue	3,662	2,808	2,783	2,200	1,594	1,320
Revenue Growth (YoY)	28.64%	0.92%	26.48%	38.02%	20.79%	-12.65%
Cost of Revenue	3,019	2,198	2,111	1,696	1,227	858.18
Gross Profit	642.58	610.82	671.82	503.69	367.13	461.47
Selling, General & Admin	172.34	186.1	127.68	106.63	80.71	66.58
Research & Development	138.98	128.41	124.28	99.71	84.23	65.03
Other Operating Expenses	5.88	4.85	6.33	-8.96	8.11	9.18
Operating Expenses	323.58	337.97	258.46	204.27	178.96	141.16
Operating Income	319.01	272.84	413.36	299.43	188.17	320.31
Interest Expense	-80.45	-33.45	-37.15	-14.24	-3.9	-8.44
Interest & Investment Income	19.98	32.12	28.27	48.53	57.7	24.23
Currency Exchange Gain (Loss)	15.9	15.9	7.21	26.45	-2.55	-6.52
Other Non Operating Income (Expenses)	6.12	-1.07	-0.86	-4.84	-0.44	-0.36
EBT Excluding Unusual Items	280.56	286.35	410.82	355.33	238.98	329.21
Gain (Loss) on Sale of Investments	5.54	-1.76	5.3	-10.27	1.78	1.99
Gain (Loss) on Sale of Assets	0.18	-0.14	-0.01	0.03	0.05	-0.24
Asset Writedown	-2.96	-0.49	-4.27	-2.31	-1.39	-1.38
Other Unusual Items	2.61	2.61	10.56	-	14.64	18.93
Pretax Income	285.93	286.57	422.4	342.78	254.07	348.52
Income Tax Expense	33.9	17.78	50.02	23.5	17.36	41.35
Earnings From Continuing Operations	252.03	268.79	372.38	319.28	236.71	307.17
Minority Interest in Earnings	-2.08	-0.31	-0.93	-	-	-
Net Income	249.95	268.48	371.45	319.28	236.71	307.17
Net Income to Common	249.95	268.48	371.45	319.28	236.71	307.17
Net Income Growth	-11.87%	-27.72%	16.34%	34.88%	-22.94%	13.72%
Shares Outstanding (Basic)	297	298	297	296	288	223
Shares Outstanding (Diluted)	323	378	297	296	288	223
Shares Change (YoY)	-8.56%	27.25%	0.23%	3.09%	28.98%	0.11%
EPS (Basic)	0.84	0.90	1.25	1.08	0.82	1.38
EPS (Diluted)	0.77	0.71	1.25	1.08	0.82	1.38
EPS Growth	-3.62%	-43.20%	16.07%	30.84%	-40.25%	13.60%
Free Cash Flow	-227.84	-1,283	-71.23	-267.77	-96.61	82.29
Free Cash Flow Per Share	-0.70	-3.39	-0.24	-0.90	-0.34	0.37
Dividend Per Share	0.700	0.500	0.538	0.462	0.330	0.393
Dividend Growth	29.99%	-7.15%	16.68%	40.02%	-16.02%	66.67%
Gross Margin	17.55%	21.75%	24.14%	22.89%	23.03%	34.97%
Operating Margin	8.71%	9.71%	14.85%	13.61%	11.80%	24.27%
Profit Margin	6.83%	9.56%	13.35%	14.51%	14.85%	23.28%
Free Cash Flow Margin	-6.22%	-45.69%	-2.56%	-12.17%	-6.06%	6.24%
EBITDA	538.15	472.14	586.2	404.88	272.57	380.4
EBITDA Margin	14.70%	16.81%	21.07%	18.40%	17.10%	28.82%
D&A For EBITDA	219.14	199.3	172.84	105.45	84.4	60.08
EBIT	319.01	272.84	413.36	299.43	188.17	320.31
EBIT Margin	8.71%	9.71%	14.85%	13.61%	11.80%	24.27%
Effective Tax Rate	11.86%	6.20%	11.84%	6.86%	6.83%	11.87%
Revenue as Reported	3,662	2,808	2,783	2,200	1,594	1,320
Advertising Expenses	-	7.95	7.89	9.97	6.92	0.49

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.